Discuss the recent clinical trials in advanced and metastatic melanoma and their application in practice.

The faculty for this activity are listed below:

Genevieve Boland, MD (Planner, Moderator)

Massachusetts General Hospital

Tawnya Bowles, MD (Planner, Presenter)

Intermountain Healthcare

Craig Slingluff, MD (Planner, Presenter)

University of Virginia

This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with melanoma.

At the conclusion of this activity, participants should be able to:

• Understand the efficacy and key toxicities of systemic therapy for advanced and metastatic melanoma.
• Identify patients appropriate for melanoma metastasectomy
• Summarize treatment options for intransit melanoma
• Understand clinical trials for surgical management and adjuvant therapy for localized melanoma

The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Society of Surgical Oncology designates this internet enduring material for a maximum of .75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The SSO has approved this activity for up to .75 self-assessment credit which meets the requirement of the self-assessment component of the American Board of Surgery (ABS) Continuous Certification Program.

This activity consists educational content, a self-assessment exam, and an evaluation. Learners must view the activity content, complete the self-assessment exam and achieve a minimum score of 75%. Learners will be able to review the content and repeat the self-assessment exam as many times as needed. Upon achieving a score of 75% or higher, learners will be asked to complete a post-activity evaluation. A certificate of credit or participation will be available upon successful submission of the post-activity evaluation.

The estimated time to complete this entire activity is  .75 hours.

Release Date

           September 21, 2020

Expiration Date

           September 21, 2021

In accordance with the ACCME’s Accreditation Criteria, the Society of Surgical Oncology must ensure that anyone in position to control the content of this educational activity has disclosed all financial relationships with a commercial interest. All educational planners, authors, reviewers, and other individuals in a position to control or influence the content of this activity were required to disclose all financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of financial relationships of a spouse or partner. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.” ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The ACCME also requires that the Society of Surgical Oncology resolve any reported conflict of interest and ensure the educational content of this activity is vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your post-activity evaluation form.

All identified conflicts of interests have been resolved.

Planners, Moderators and Faculty

Genevieve Boland, MD has disclosed the following financial relationship: Novartis – Scientific Advisory Board and Speaker.

Tawnya Bowles, MD has disclosed no financial relationships.

Craig Slingluff, MD has disclosed the following financial relationship: Polynoma – Travel Reimbursement; UVA Licensing and Venture Groups – Royalties (Co-inventor on peptides for use in cancer vaccines).

Reviewers

Andrea Porpiglia, MD has disclosed no financial relationships.

Ching-Wei David Tzeng, MD has disclosed no financial relationships.

Staff

Patti Stella, CAE, CHCP, Director of Education, Society of Surgical Oncology, has disclosed the following financial relationships: Horizon Pharmaceutical PLC – Stocks; Biotech – Stocks.

The primary purpose of the Society of Surgical Oncology's enduring material is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.

This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.

For information about the Society of Surgical Oncology’s privacy policy and associated disclaimer, please visit this site: http://www.surgonc.org/disclaimer.

System requirements for this activity can be found by clicking the Help button. For technical support, please contact us at expertED@surgonc.org